51. BCLC-B Subclassification and the Hong Kong Liver Cancer System in Intermediate Hepatocellular Carcinoma: Identifying Candidates for Curative Therapy.
- Author
-
Longo L, Rodrigues de Freitas LB, Santos D, Grivicich I, and Álvares-da-Silva MR
- Subjects
- Adult, Aged, Brazil, Carcinoma, Hepatocellular mortality, Chemoembolization, Therapeutic mortality, Cross-Sectional Studies, Female, Humans, Kaplan-Meier Estimate, Liver Neoplasms mortality, Male, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Palliative Care, Patient Selection, Retrospective Studies, Risk Assessment, Survival Analysis, Treatment Outcome, Carcinoma, Hepatocellular classification, Carcinoma, Hepatocellular therapy, Chemoembolization, Therapeutic methods, Liver Neoplasms classification, Liver Neoplasms therapy
- Abstract
Introduction: The intermediate stage of the Barcelona Clinic Liver Cancer (BCLC) classification includes a heterogenous population of patients with hepatocellular carcinoma (HCC), and palliative treatment with transarterial chemoembolization is recommended for all of them. In this regard, 2 other classifications could be useful, the subclassification BCLC-B (SUB) and the classification Hong Kong Liver Cancer (HKLC)., Objective: To determine the indication of curative or palliative treatment between SUB and HKLC in BCLC-B patients., Patients and Methods: A retrospective study in HCC patients seen between 2011 and 2016 in southern Brazil. Demographic, clinical, and laboratory data were collected. HCC staging was performed with BCLC, SUB, and HKLC., Results: A total of 570 patients with HCC were assessed, of whom 95 were classified as BCLC-B: 25 (26.0%) B1, 48 (50.5%) B2, 9 (9.5%) B3, and 13 (13.7%) B4. Overall median survival was 21.1 (95% confidence interval, 14.2-28.0) months. Median survival was higher for BCLC-B1 patients than in subgroups B3 (P=0.046) and B4 (P=0.001), and this was also seen for B2 versus B4 (P=0.044). Regarding the HKLC classification, a significantly higher median survival was observed for HKLC-I and HKLC-IIB in relation to the categories HKLC-IIIA (P<0.001 and 0.004, respectively) and HKLC-IIIB (P<0.001 and 0.006, respectively). When HKLC was applied, the following were identified as candidates for curative treatment: BCLC-B1, 24 (96.0%); BCLC-B2, 26 (54.2%); BCLC-B3, 0 (0%); and BCLC-B4, 3 (23.1%)., Conclusion: In intermediate HCC, SUB was able to identify a subset of patients with a higher overall survival. According to HKLC, 55.8% of BCLC-B patients could receive curative treatment.
- Published
- 2019
- Full Text
- View/download PDF